Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.49 |
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976355 | 0.88 | SLC18A3 (0.47) | — | |
| SCHEMBL1171605 | 0.88 | SLC18A3 (0.47) | — | |
| SCHEMBL4975063 | 0.87 | IDO1 (0.48) | CYP2C9 | |
| SCHEMBL3900477 | 0.87 | IDO1 (0.48) | CYP2C9 | |
| SCHEMBL432492 | 0.80 | ESR2 (0.53) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL660938 | 0.80 | ESR2 (0.53) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL603381 | 0.78 | DRD2 (0.50) | CYP2C9 | |
| SCHEMBL5967397 | 0.78 | — | — | |
| SCHEMBL6270743 | 0.78 | — | — | |
| Acetic Acid SCHEMBL6249037 | 0.76 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ESR2 4767/4885ESR1 4844/4885CYP3A4 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.